HOOKIPA Pharma to delist from Nasdaq and liquidate following Gilead asset sale
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 18 2025
0mins
Source: SeekingAlpha
Delisting Announcement: HOOKIPA Pharma has announced its voluntary delisting from the Nasdaq Capital Market and plans to deregister its common stock, following an asset sale agreement with Gilead Sciences for key assets related to hepatitis B and HIV programs.
Future Plans: A special stockholder meeting is scheduled for July 29, 2025, to vote on the asset sale and potential company dissolution, with plans to file for dissolution in Delaware and begin liquidation proceedings upon approval.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like undefined with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
